<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="30621">Arsenic trioxide</z:chebi> (ATO) has been found to be an effective treatment for <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> patients and is being tested for treating other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously shown that AML1/MDS1/EVI1 (AME), a fusion gene generated by a t(3;21)(q26;q22) translocation found in patients with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> during <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), impairs hematopoiesis and eventually induces an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in mice </plain></SENT>
<SENT sid="2" pm="."><plain>Both fusion partners of AME, AML1 and MDS1/EVI1, encode transcription factors and are also targets of a variety of genetic abnormalities in human <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, aberrant expression of ectopic <z:mp ids='MP_0001799'>viral</z:mp> integration site 1 (EVI1) has also been found in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, such as ovarian and <z:hpo ids='HP_0003003'>colon cancers</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we examined whether ATO could target AME and related oncoproteins </plain></SENT>
<SENT sid="5" pm="."><plain>We found that ATO used at therapeutic levels degrades AME </plain></SENT>
<SENT sid="6" pm="."><plain>The ATO treatment induces differentiation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in AME leukemic cells in vitro as well as reduces <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load and increases the survival of mice transplanted with these cells </plain></SENT>
<SENT sid="7" pm="."><plain>We further found that ATO targets AME via both <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> 1 (MDS1) and EVI1 moieties and degrades EVI1 via the ubiquitin-proteasome pathway and MDS1 in a proteasome-independent manner </plain></SENT>
<SENT sid="8" pm="."><plain>Our results suggest that ATO could be used as a part of targeted therapy for AME-, AML1/MDS1-, MDS1/EVI1-, and EVI1-positive human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>